FDA approves Fluzakura for previously treated metastatic colorectal cancer
The Food and Drug Administration (FDA) has approved Fluzakura (fruquintinib) for the treatment of some adults with metastatic colorectal cancer (mCRC), biopharmaceutical company Takeda Pharmaceutical announced in a news release. Patients are eligible for treatment with Fluzacra, an oral targeted therapy, after treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy and anti-VEGF therapy. Patients with wild-type RAS […]
Japan seeks approval of fruquintinib for previously treated metastatic colorectal cancer
Colorectal cancer © Stock.adobe.com A new drug application (NDA) has been submitted to Japan’s Ministry of Health, Labor and Welfare seeking approval of fruquintinib (Elnato) for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC).1 The NDA is supported by data from the Phase 3 FRESCO-2 study (NCT04322539) and results from the […]